ArticleBMC ophthalmology2025
Application of SS-OCTA to evaluate the effects of long-term hydroxychloroquine treatment on retinal structure and microcirculation in patients with systemic lupus erythematosus.
Article in BMC ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
proposeThe application of swept-source optical coherence tomography angiography (SS-OCTA) technique is used to detect the effects of long-term use of hydroxychloroquine (HCQ) on retinal structure and microcirculation in patients with systemic lupus erythematosus (SLE) before visual dysfunction occurs.
methodsRetrospective case-control study. A total of 73 SLE patients (73 eyes) who had taken HCQ regularly for a long period of time were included as the SLE patient group, while 21 healthy individuals (21 eyes) were included as the control group. Based on the duration of HCQ use (HCQ course), the SLE patient group was divided into baseline group (6 months ≤ medication time < 1 year), low-risk group ( 1 year ≤ medication time < 5 years), and high-risk group (medication time ≥ 5 years). All participants underwent bilateral SS-OCTA macular imaging (6 mm*6 mm), slit-lamp examination, non-contact tonometry, computerized visual field (30 - 2) test, and fundus autofluorescence imaging (FAF).
resultsCompared among the groups, the full-layer retinal thickness and superficial blood vessel density of the fovea, below the inner circle, temporal side of the outer circle and above the outer circle decreased in the macular area (6 mm*6 mm) in high-risk group of SLE patients, while the area and circumference of FAZ increased (P < 0.0125). Correlation analysis suggested that the duration of SLE disease and HCQ cumulative dose were negatively correlated with superficial retinal capillary plexus vessel density (SCP-VD) in the three regions of inner retina, full-layer retinal thickness in the fovea, fovea, temporal side of the inner circle, and above the inner circle (r < 0,P < 0.05), and positively correlated with the area and circumference of FAZ (r > 0,P < 0.05).
conclusionAnalysis by SS-OCTA examination showed that long-term HCQ treatment had adverse effects on the inner retina, SCP-VD and FAZ parameters in subclinical SLE patients without visual impairment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.